227 related articles for article (PubMed ID: 29753351)
1. Evaluating and Valuing Drugs for Rare Conditions: No Easy Answers.
Ollendorf DA; Chapman RH; Pearson SD
Value Health; 2018 May; 21(5):547-552. PubMed ID: 29753351
[TBL] [Abstract][Full Text] [Related]
2. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
Rodriguez-Monguio R; Spargo T; Seoane-Vazquez E
Orphanet J Rare Dis; 2017 Jan; 12(1):1. PubMed ID: 28057032
[TBL] [Abstract][Full Text] [Related]
3. International experiences in multicriteria decision analysis (MCDA) for evaluating orphan drugs: a scoping review.
Lasalvia P; Prieto-Pinto L; Moreno M; Castrillón J; Romano G; Garzón-Orjuela N; Rosselli D
Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):409-420. PubMed ID: 31210065
[No Abstract] [Full Text] [Related]
4. Pharmaceutical expenditure on drugs for rare diseases in Canada: a historical (2007-13) and prospective (2014-18) MIDAS sales data analysis.
Divino V; DeKoven M; Kleinrock M; Wade RL; Kim T; Kaura S
Orphanet J Rare Dis; 2016 May; 11(1):68. PubMed ID: 27207271
[TBL] [Abstract][Full Text] [Related]
5. A discrete choice experiment investigating preferences for funding drugs used to treat orphan diseases: an exploratory study.
Mentzakis E; Stefanowska P; Hurley J
Health Econ Policy Law; 2011 Jul; 6(3):405-33. PubMed ID: 21205401
[TBL] [Abstract][Full Text] [Related]
6. Economic considerations in the provision of treatments for rare diseases.
McCabe C; Edlin R; Round J
Adv Exp Med Biol; 2010; 686():211-22. PubMed ID: 20824448
[TBL] [Abstract][Full Text] [Related]
7. Limits on use of health economic assessments for rare diseases.
Hyry HI; Stern AD; Cox TM; Roos JC
QJM; 2014 Mar; 107(3):241-5. PubMed ID: 24453281
[TBL] [Abstract][Full Text] [Related]
8. One drug to treat many diseases: unlocking the economic trap of rare diseases.
Pierzynowska K; Kamińska T; Węgrzyn G
Metab Brain Dis; 2020 Dec; 35(8):1237-1240. PubMed ID: 32926291
[TBL] [Abstract][Full Text] [Related]
9. Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries.
Zelei T; Molnár MJ; Szegedi M; Kaló Z
Orphanet J Rare Dis; 2016 Jun; 11(1):72. PubMed ID: 27259284
[TBL] [Abstract][Full Text] [Related]
10. Which orphans will find a home? The rule of rescue in resource allocation for rare diseases.
Largent EA; Pearson SD
Hastings Cent Rep; 2012; 42(1):27-34. PubMed ID: 22616398
[No Abstract] [Full Text] [Related]
11. [Authorization and reimbursement of orphan drugs in an international comparison].
Roll K; Stargardt T; Schreyögg J
Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
[TBL] [Abstract][Full Text] [Related]
12. Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?
Hughes-Wilson W; Palma A; Schuurman A; Simoens S
Orphanet J Rare Dis; 2012 Sep; 7():74. PubMed ID: 23013790
[TBL] [Abstract][Full Text] [Related]
13. Reimbursement of Drugs for Rare Diseases through the Public Healthcare System in Canada: Where Are We Now?
Menon D; Clark D; Stafinski T
Healthc Policy; 2015 Aug; 11(1):15-32. PubMed ID: 26571466
[TBL] [Abstract][Full Text] [Related]
14. Ethical dilemmas about orphan drugs for orphan diseases.
Isaacs D
J Paediatr Child Health; 2014 Apr; 50(4):249-50. PubMed ID: 24698059
[No Abstract] [Full Text] [Related]
15. Drugs for rare diseases: mixed assessment in Europe.
Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
[TBL] [Abstract][Full Text] [Related]
16. Dealing with Uncertainty and Accounting for Social Value Judgments in Assessments of Orphan Drugs: Evidence from Four European Countries.
Nicod E; Berg Brigham K; Durand-Zaleski I; Kanavos P
Value Health; 2017; 20(7):919-926. PubMed ID: 28712621
[TBL] [Abstract][Full Text] [Related]
17. Orphan drug development: an economically viable strategy for biopharma R&D.
Meekings KN; Williams CS; Arrowsmith JE
Drug Discov Today; 2012 Jul; 17(13-14):660-4. PubMed ID: 22366309
[TBL] [Abstract][Full Text] [Related]
18. The challenges of orphan drugs and orphan diseases: real and imagined.
Hudson I; Breckenridge A
Clin Pharmacol Ther; 2012 Aug; 92(2):151-3. PubMed ID: 22814659
[TBL] [Abstract][Full Text] [Related]
19. Estimating the clinical cost of drug development for orphan versus non-orphan drugs.
Jayasundara K; Hollis A; Krahn M; Mamdani M; Hoch JS; Grootendorst P
Orphanet J Rare Dis; 2019 Jan; 14(1):12. PubMed ID: 30630499
[TBL] [Abstract][Full Text] [Related]
20. Orphan drugs revisited.
McCabe C; Tsuchiya A; Claxton K; Raftery J
QJM; 2006 May; 99(5):341-5; discussion 350-1. PubMed ID: 16504983
[No Abstract] [Full Text] [Related]
[Next] [New Search]